Table 3 The clinical features and outcomes of HTLV1 infection for renal transplantation (case 1-case 4)
HTLV-1 status recipient donor | Day of renal transplantation | Immunosuppressive drugs | ATL or HAM development | The day of ATL development after renal transplantation | FCM | ATL diagnosis | Treatment for ATL | Outcome of ATL | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Southern blot analysis | Pathological analysis | FK withdrawal | Chemotherapy | ||||||||||
Case 1 | 60 age, male | HTLV-positive recipient ( +) | – | July 2017 | FK | ATL development (skin, lung) | 1016 days (2 years and 9 months) | None | Monoclonal band | Polymorphic pattern showing CD3 + 4 + in skin | FK withdrawal (3.0 mg per day → 2.0 mg per day) | CHOP therapy CBSCT (FLU/MEL/TBI, FK + MMF) | Dead (Mucor infection) (101 days) |
Case 2 | 75 age, female | – | HTLV-1-positive donor ( +) | September 2018 | FK | ATL development (LNs, BM) | 1195 days (3 years and 3 months) | CD3 + 4 + 8 + 30 + 25-phenotype | Monoclonal band | Polymorphic pattern in BM | FK withdrawal (2.5 mg per day → 1.5 mg per day) | mPSL | Dead (5 days) |
Case 3 | 65 age, male | – | HTLV-1-positive donor ( +) | April 2020 | FK | No ATL and no HAM development (HTLV-1 copies: 10 copies) | No | None | None | None | No | Follow-up | Alive |
Case 4 | 60 age, female | HTLV-positive recipient ( +) | HTLV-1-positive donor ( +) | September 2021 | FK | No ATL and no HAM development (HTLV-1 copies;10 copies) | No | None | None | None | No | Follow-up | Alive |